| Product Name | Linaclotide |
| Synonyms | Linzess, Constella, MD-1100, CY-14 |
| CAS Number | 851199-59-2 |
| Sequence (3-Letter) | H-Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH (disulfides Cys1–Cys6, Cys2–Cys10, Cys5–Cys13) |
| Sequence (1-Letter) | CCEYCCNPACTGCY (3 disulfides: 1–6, 2–10, 5–13; heterodetic cyclic) |
| Molecular Formula | C₅₉H₇₉N₁₅O₂₁S₆ |
| Molecular Weight | 1526.74 |
| Category | Drug Peptide – Guanylate Cyclase-C Agonist |
| Purity | ≥98% (by HPLC) |
| Appearance | White to off-white powder |
| Counter Ion | Acetate / free acid (salt form per specification) |
| Peptide Content | ≥80% (per specification) |
| Solubility | Soluble in water |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – g (research quantities; larger scale on enquiry) |
| QC Documentation | COA, HPLC, MS identity, disulfide-connectivity confirmation (additional API/regulatory documentation on request) |
| Usage | For research and pharmaceutical development use, and as a reference standard or active pharmaceutical ingredient for manufacturing. Not for human or veterinary use; not for sale to patients. Any therapeutic use is subject to applicable regulatory approval. |
Linaclotide is a synthetic 14-amino-acid peptide and a guanylate cyclase-C (GC-C) agonist, known as a medicine under the brand names Linzess and Constella (CAS 851199-59-2). Its sequence is CCEYCCNPACTGCY, a cyclic peptide held together by three disulfide bonds, and it mimics the body's own intestinal peptides guanylin and uroguanylin. We supply it as a white powder for research and pharmaceutical development.
Linaclotide acts on guanylate cyclase-C receptors on the inner surface of the gut lining. Switching these receptors on raises cGMP inside the cells, which drives the secretion of chloride, bicarbonate, and water into the bowel and speeds up transit. The same pathway also lowers the sensitivity of the pain-sensing nerves in the gut. Because it is barely absorbed, it works locally in the intestine.
Clinically, linaclotide is used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. This is background information only; the material we supply is for research and pharmaceutical manufacturing use, and is not for human or veterinary use and not for sale to patients.
We supply Linaclotide with a certificate of analysis, HPLC purity data, and mass-spec identity confirmation, and we can confirm the disulfide connectivity. Additional documentation for API and regulatory work is available on request, and purity can be set to your specification.
Yes. We manufacture Linaclotide in-house. With three disulfide bonds it is a demanding synthesis and fold, and we can discuss the right approach and scale for your needs. Contact us with your required purity and quantity for a quote.
Linaclotide is a synthetic 14-amino-acid peptide and a guanylate cyclase-C (GC-C) agonist, the first medicine of its class. It is known under the brand names Linzess and Constella and is taken by mouth. We supply it as a raw material for research and pharmaceutical development.
Linaclotide is a small heterodetic cyclic peptide of 14 residues with the sequence CCEYCCNPACTGCY and a free C-terminus. Its six cysteines form three disulfide bonds, Cys1-Cys6, Cys2-Cys10, and Cys5-Cys13, which fold it into a compact, rigid shape. It is a structural mimic of the body's own intestinal peptides guanylin and uroguanylin. Its CAS number is 851199-59-2, its molecular formula is C59H79N15O21S6, and its molecular weight is about 1527.
Linaclotide binds and activates guanylate cyclase-C receptors on the luminal surface of the intestinal lining. Activation raises the level of cyclic GMP (cGMP) inside the epithelial cells, which opens the CFTR channel and drives secretion of chloride, bicarbonate, and water into the gut lumen, accelerating intestinal transit. The same cGMP signalling also reduces the sensitivity of the pain-carrying nerves in the bowel. Linaclotide is acid-stable, protease-resistant, and minimally absorbed, so it acts locally in the intestine rather than throughout the body.
Linaclotide is used clinically to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. This information is provided as scientific and reference background only. The material supplied by SynPeptide is intended for research and pharmaceutical manufacturing, is not for human or veterinary use, and is not for sale to patients; any therapeutic use is subject to applicable regulatory approval.
With three disulfide bonds that have to pair in one specific pattern, linaclotide is a demanding, regioselective synthesis and fold. We make it by solid-phase synthesis with controlled disulfide formation, and supply it with a certificate of analysis, HPLC purity data, mass-spectrometry identity confirmation, and confirmation of disulfide connectivity, with further documentation available to support active pharmaceutical ingredient and regulatory work.
We manufacture Linaclotide to order, including the three-disulfide fold. For related capabilities, see drug peptides, custom peptide synthesis, peptide modification, and cyclic peptides. Material is supplied for research and pharmaceutical manufacturing use only.
